title: Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.
abstract: Amantadine has been used for more than 20 years in the symptomatic treatment of Parkinson's disease (PD). Several recent discoveries suggest that amantadine could also have a neuroprotective effect in PD. We studied survival in all parkinsonism (including PD and other parkinsonian syndromes) patients attending a single clinic, employing standard survival curves and a Cox regression model, to identify independent predictive variables for survival (while taking into account factors potentially associated with both outcome and treatment selection). Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit. Amantadine use was an independent predictor of improved survival (p < 0.01). Improved survival was also associated with a higher 10-year expected survival (based on age, gender, and birth year), absence of dementia, type of parkinsonism = PD, and low Hoehn and Yahr stage (I or II) at initial neurologic visit (all p < 0.01); these additional factors occurred in statistically similar proportions in the groups that were and were not treated with amantadine. The association of improved survival with amantadine use may stem from symptomatic benefit or may reflect a "neuroprotective" effect, mediated through N-methyl-D-aspartate (NMDA) receptor antagonism, dopamine uptake blockade activity, or other mechanisms. Our preliminary findings suggest that a prospective, controlled, randomized trial of amantadine's effects on PD progression is warranted.
authors.affiliation: Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Uitti
authors.forename: A H
authors.initials: AH
authors.lastname: Rajput
authors.forename: J E
authors.initials: JE
authors.lastname: Ahlskog
authors.forename: K P
authors.initials: KP
authors.lastname: Offord
authors.forename: D R
authors.initials: DR
authors.lastname: Schroeder
authors.forename: M M
authors.initials: MM
authors.lastname: Ho
authors.forename: M
authors.initials: M
authors.lastname: Prasad
authors.forename: A
authors.initials: A
authors.lastname: Rajput
authors.forename: P
authors.initials: P
authors.lastname: Basran
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018450:Disease Progression; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D008959:Models, Neurological; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D016019:Survival Analysis
chemical_list: D000978:Antiparkinson Agents; D018765:Dopamine Uptake Inhibitors; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D000547:Amantadine